Clinical trialNCT02104817CompletedPhase 3Interventional

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

SponsorAstraZenecaEnrollment13,078Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Michael Lincoff, MD
The Cleveland Clinic
Principal Investigator
clinicaltrials.gov ↗
Stephen Nicholls, MD
MonashHeart
Principal Investigator
clinicaltrials.gov ↗
Steven Nissen, MD
The Cleveland Clinic
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

684 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Research Site
Adelaide, Australia
Research Site
Blacktown, Australia
Research Site
Box Hill, Australia
Research Site
Cowra, Australia
Research Site
Forbes, Australia
Research Site
Fremantle, Australia
Research Site
Herston, Australia
Research Site
Joondalup, Australia
Research Site
Maroubra, Australia
Research Site
Milton, Australia
Research Site
South Brisbane, Australia
Research Site
Southport, Australia
Research Site
Tumbi Vmbi, Australia
Research Site
Wollongong, Australia

Belgium

Research Site
Aalst, Belgium
Research Site
Antwerp, Belgium
Research Site
Bruges, Belgium
Research Site
Brussels, Belgium
Research Site
Brussels, Belgium
Research Site
Genk, Belgium
Research Site
Halen, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Mol, Belgium
Research Site
Mons, Belgium

Canada

Research Site
New Westminster, British Columbia, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Barrie, Ontario, Canada
Research Site
Brampton, Ontario, Canada
Research Site
Cambridge, Ontario, Canada
Research Site
Etobicoke, Ontario, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
North York, Ontario, Canada
Research Site
Peterborough, Ontario, Canada
Research Site
Thornhill, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Granby, Quebec, Canada
Research Site
Laval, Quebec, Canada

644 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Oct 2014
Primary completion: 27 May 2020
Completion: 27 May 2020
Last update posted: 17 Aug 2021
Registered enrollment: 13,078
Registry id: NCT02104817

Cross-registrations

EU-CTR / CTIS (EudraCT)2014-001069-28

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.